FYMRALIN

Serial Number 88064191
606

Registration Progress

Application Filed
Aug 3, 2018
Under Examination
Jun 25, 2019
Approved for Publication
Dec 25, 2018
Published for Opposition
Dec 25, 2018
Registered

Trademark Image

FYMRALIN

Basic Information

Serial Number
88064191
Filing Date
August 3, 2018
Published for Opposition
December 25, 2018
Abandonment Date
August 1, 2022
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Aug 1, 2022
Classes
005

Rights Holder

TONIX Pharmaceuticals, Inc.

03
Address
509 Madison Avenue, Suite 306
New York, NY 10022

Ownership History

TONIX Pharmaceuticals, Inc.

Original Applicant
03
New York, NY

TONIX Pharmaceuticals, Inc.

Owner at Publication
03
New York, NY

Legal Representation

Attorney
Francis J. Duffin

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

33 events
Date Code Type Description Documents
Aug 1, 2022 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Aug 1, 2022 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Dec 31, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 30, 2021 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Dec 30, 2021 EX5G S SOU EXTENSION 5 GRANTED Loading...
Dec 21, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 21, 2021 EXT5 S SOU EXTENSION 5 FILED Loading...
Jun 29, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 25, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 25, 2021 EXT4 S SOU EXTENSION 4 FILED Loading...
Jun 25, 2021 EX4G S SOU EXTENSION 4 GRANTED Loading...
Dec 24, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 22, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 22, 2020 EXT3 S SOU EXTENSION 3 FILED Loading...
Dec 22, 2020 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jun 18, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 16, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 16, 2020 EXT2 S SOU EXTENSION 2 FILED Loading...
Jun 16, 2020 EX2G S SOU EXTENSION 2 GRANTED Loading...
Dec 11, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 9, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 9, 2019 EXT1 S SOU EXTENSION 1 FILED Loading...
Dec 9, 2019 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jun 25, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
May 5, 2019 ETOP T EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED Loading...
Jan 8, 2019 ETOF T EXTENSION OF TIME TO OPPOSE RECEIVED Loading...
Dec 25, 2018 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 25, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 5, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 21, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 21, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 9, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 7, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of sleep disorders, fibromyalgia, post-traumatic stress disorder, functional somatic disorder, disorders of the nervous system, disorders of the musculo-skeletal system, disorders of the endocrine system, disorders of the musculoskeletal system, neurological disorders, hormonal disorder, psychiatric-related diseases and disorders
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005